ImmuPharma plc (LON:IMM – Get Free Report) shares traded up 4.3% during trading on Thursday . The company traded as high as GBX 5.30 ($0.07) and last traded at GBX 5.10 ($0.06). Approximately 15,040,100 shares were traded during mid-day trading, a decline of 41% from the average session volume of 25,307,068 shares. The stock had previously closed at GBX 4.89 ($0.06).
ImmuPharma Trading Up 12.5 %
The firm’s 50 day moving average price is GBX 1.98 and its two-hundred day moving average price is GBX 1.80. The company has a market capitalization of £22.90 million, a price-to-earnings ratio of -550.00 and a beta of 1.53.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Articles
- Five stocks we like better than ImmuPharma
- Following Congress Stock Trades
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- Best Aerospace Stocks Investing
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
- What Are Dividend Champions? How to Invest in the Champions
- Microsoft Stock Breaks Trend, But It Doesn’t Matter—Here’s Why
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
